Prurigo Nodularis Treatment Market Size, Share, and Trends 2024 to 2033

Prurigo Nodularis Treatment Market (By Product Type: Antihistamines, Capsaicin Cream, Corticosteroids, Emollients, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 4279
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Prurigo Nodularis Treatment Market 

5.1. COVID-19 Landscape: Prurigo Nodularis Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Prurigo Nodularis Treatment Market, By Product Type

8.1. Prurigo Nodularis Treatment Market, by Product Type, 2024-2033

8.1.1. Antihistamines

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Capsaicin Cream

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Corticosteroids

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Emollients

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Prurigo Nodularis Treatment Market, By Distribution Channel

9.1. Prurigo Nodularis Treatment Market, by Distribution Channel, 2024-2033

9.1.1. Hospital Pharmacies

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Retail Pharmacies

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Online Pharmacies

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Prurigo Nodularis Treatment Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Product Type (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 11. Company Profiles

11.1. Bayer AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Celgene Corporation

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Glaxo Smith Kline plc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Johnson & Johnson Services Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Merk & Co. Inc

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Pfizer Inc

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Sanofi SA

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Teva Pharmaceutical Industries Ltd

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client